| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
AT1 Receptor; As an ester derivative of olmesartan, olmesartan methyl ester targets the angiotensin II type 1 receptor (AT1 receptor). The active metabolite olmesartan exerts its antihypertensive effect by selectively blocking the binding of angiotensin II to AT1 receptors, thereby inhibiting vasoconstriction and aldosterone release. Olmesartan exhibits potent AT1 receptor binding with an IC₅₀ of approximately 7.7 nM. Studies have shown that olmesartan methyl ester itself is a substrate for OATP2B1 (organic anion transporting polypeptide 2B1), a transporter expressed in the small intestine involved in drug absorption.
|
|---|---|
| ln Vitro |
Olmesartan methyl ester requires in vivo hydrolysis to exert its pharmacological activity as an ester derivative. Studies demonstrate that olmesartan methyl ester exhibits significantly higher intestinal permeability compared to olmesartan: its uptake in Caco-2 cells is markedly higher, and its permeability in rat jejunum is superior to the parent drug. This property is attributed to its role as an OATP2B1 substrate, closely related to the expression of this transporter. The parent compound olmesartan exhibits potent AT1 receptor antagonism with an IC₅₀ of 7.7 nM in vitro.
|
| ln Vivo |
As a prodrug form of olmesartan, olmesartan methyl ester is converted in vivo to the active metabolite to exert its antihypertensive effects. The onset of action occurs 1-2 hours after administration, with peak effects observed approximately 6-8 hours post-dose, and the antihypertensive effects last up to 24 hours. Studies have confirmed that olmesartan methyl ester exhibits improved intestinal absorption compared to olmesartan, mediated by the OATP2B1 transporter, significantly enhancing the oral bioavailability of the drug.
|
| Enzyme Assay |
The binding affinity of olmesartan methyl ester for the AT1 receptor can be assessed using radioligand binding assays following protocols for the parent compound. Typical AT1 receptor binding assays use membranes from cells expressing human AT1 receptors (e.g., CHO cell membranes). Membrane proteins are incubated with [¹²⁵I]-labeled angiotensin II tracer and various concentrations of olmesartan methyl ester (0.1 nM-100 μM) in binding buffer. Following incubation at room temperature for 60-120 minutes, the reaction is terminated by vacuum filtration, filters are washed to remove unbound tracer, and retained radioactivity is measured to calculate specific binding inhibition rates.
|
| Cell Assay |
Cellular assays for olmesartan methyl ester can use the Caco-2 cell monolayer permeability model to evaluate intestinal absorption properties. Caco-2 cells are seeded onto Transwell inserts and cultured until tight monolayer formation (approximately 21 days). Various concentrations of olmesartan methyl ester (e.g., 1-100 μM) are added to the apical side, and after incubation at 37°C for 2 hours, samples are collected from the basolateral side and drug concentrations are determined by HPLC-MS/MS to calculate apparent permeability coefficients (Papp). Additionally, OATP2B1-overexpressing HEK293 cells can be used to evaluate uptake activity as a transporter substrate.
|
| ADME/Pharmacokinetics |
Olmesartan methyl ester, as a prodrug, has an oral bioavailability of less than 26%. The compound is rapidly hydrolyzed in vivo to the active metabolite olmesartan, which has a half-life of approximately 13 hours, supporting once-daily dosing. Olmesartan methyl ester exhibits improved intestinal permeability compared to olmesartan, mediated by OATP2B1 transporter-facilitated absorption. In rat jejunum, olmesartan methyl ester shows significantly higher permeability than olmesartan, suggesting that esterification improves the oral absorption properties of the drug. The compound has a solubility of 100 mg/mL (~217.14 mM) in DMSO, with a common in vivo injection formulation including DMSO : Tween 80 : saline = 10 : 5 : 85.
|
| Toxicity/Toxicokinetics |
According to the safety data sheet for olmesartan methyl ester, the compound exhibits acute oral toxicity (Category 4, H302) and is very toxic to aquatic life with long-lasting effects (Category 1, H400/H410). It may cause skin irritation (H315) and serious eye irritation (H319). The compound is not listed as a carcinogen by IARC, NTP, ACGIH, or OSHA, and no evidence suggests reproductive or genotoxic toxicity in standard evaluations. The powder can be stored at -20°C for 3 years, at 4°C for 2 years, and in solution at -80°C for 6 months. Protective gloves and eye protection should be worn during handling, and release to the environment should be avoided.
|
| References |
|
| Molecular Formula |
C25H28N6O3
|
|---|---|
| Molecular Weight |
460.53
|
| Exact Mass |
460.222
|
| Elemental Analysis |
C, 65.20; H, 6.13; N, 18.25; O, 10.42
|
| CAS # |
1347262-29-6
|
| Related CAS # |
144689-24-7; 1347262-29-6 (methyl ester ); 144689-63-4 (medoxomil)
|
| PubChem CID |
71465208
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
712.0±70.0 °C at 760 mmHg
|
| Flash Point |
384.4±35.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.645
|
| LogP |
4.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
671
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OC)C(C)(C)O
|
| InChi Key |
XFIYSFZDSWUHEO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H28N6O3/c1-5-8-20-26-22(25(2,3)33)21(24(32)34-4)31(20)15-16-11-13-17(14-12-16)18-9-6-7-10-19(18)23-27-29-30-28-23/h6-7,9-14,33H,5,8,15H2,1-4H3,(H,27,28,29,30)
|
| Chemical Name |
methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
|
| Synonyms |
Olmesartan Methyl Ester; 1347262-29-6; methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid Methyl Ester; Olmesartan Impurity 20;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (217.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1714 mL | 10.8571 mL | 21.7141 mL | |
| 5 mM | 0.4343 mL | 2.1714 mL | 4.3428 mL | |
| 10 mM | 0.2171 mL | 1.0857 mL | 2.1714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
